Category: News

In January, we added 117 citations in DIDB, including 54 in vitro (with 21 articles published in January 2024) and 63 in vivo articles (with 39 articles published in January 2024).

6 NDA/BLAs approved in 2023, including capivasertib (TRUQAP), efbemalenograstim (RYZNEUTA), epcoritamab (EPKINLY), mirikizumab (OMVOH), nirogacestat (OGSIVEO), and rezafungin (REZZAYO), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase has been updated in January 2024, and is available in the DIDB Resource Center.

In this update, 42 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates, and 3 compounds were strong inhibitors, which could lead to strong drug interactions mediated by CYP1A2, CYP2C19, and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In December, we added 76 citations in DIDB, including 32 in vitro (with 22 articles published in December 2023) and 44 in vivo articles (with 36 articles published in December 2023).

5 NDA/BLAs approved in 2023, including fruquintinib (FRUZAQLA), gepirone (EXXUA), repotrectinib (AUGTYRO), toripalimab (LOQTORZI), vamorolone (AGAMREE), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In November, we added 105 citations in DIDB, including 44 in vitro (with 18 articles published in November 2023) and 61 in vivo articles (with 31 articles published in November 2023).

6 NDA/BLAs: bimekizumab (BIMZELX), cipaglucosidase alfa (POMBILITI), etrasimod (VELSIPITY), motixafortide (APHEXDA), nedosiran (RIVFLOZA), zilucoplan (ZILBRYSQ).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In October, we added 110 citations in DIDB, including 47 in vitro (with 16 articles published in October 2023) and 63 in vivo articles (with 38 articles published in October 2023).

4 recently approved NDAs/BLAs were also added: elranatamab (ELREXFIO), momelotinib (OJJAARA), pozelimab (VEOPOZ), sotagliflozin (INPEFA).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in October 2023, and is available in the DIDB Resource Center.

In this update, 35 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 2 compounds were sensitive substrates and 3 compounds were strong inhibitors which could lead to strong drug interactions mediated by CYP2D6 and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In September, we added 74 citations in DIDB, including 33 in vitro (with 12 articles published in September 2023) and 41 in vivo articles (with 22 articles published in September 2023).

6 recently approved NDAs/BLAs were also added: avacincaptad pegol (IZERVAY), lotilaner (XDEMVY), nirmatrelvir and ritonavir (PAXLOVID),palovarotene (SOHONOS),  somatrogon (NGENLA), talquetamab (TALVEY).

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In August, we added 117 citations in DIDB, including 63 in vitro (with 23 articles published in August 2023) and 54 in vivo articles (with 30 articles published in August 2023).

3 recently approved NDAs/BLAs were also added: glofitamab (COLUMVI), nirsevimab (BEYFORTUS), quizartinib (VANFLYTA)

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In July, we added 110 citations in DIDB, including 55 in vitro (with 21 articles published in July 2023) and 55 in vivo articles (with 33 articles published in July 2023).

4 recently approved NDAs/BLAs were also added: flotufolastat F-18 gallium (POSLUMA), ritlecitinib (LITFULO), rozanolixizumab (RYSTIGGO), sulbactam and durlobactam (XACDURO)

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase (replacing the previous combined and individual lists of CYP/P-gp substrates and perpetrators) has been updated in July 2023, and is available in the DIDB Resource Center.

In this update, 25 compounds were identified as substates, inhibitors, and inducers of CYP enzymes and transporters (P-gp, BCRP, and OATP1B1/3). Among them, 3 compounds were sensitive substrates and could lead to strong drug interactions mediated by CYP1A2, CYP2D6, and CYP3A.

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g. dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.